Equaly’s technology platform modulates immune responses based on antigen-specific cells of the innate immune system. This opens the door to better biologicals and new immunotherapies for cancer, infectious diseases and auto-immune diseases.
As indicated by our name, Equaly aims to develop therapies accessible to everyone. We strive to cure the very heart of the disease, instead of simply alleviating symptoms.
Equaly’s strategy is defined by its vision. This means we seek partners who want to collaborate on our main objectives:
Equaly’s three main drivers all center on our ultimate goal: helping the patient find a permanent solution to their problem.